 Home > Active Ingredient News > Antitumor Therapy > BMC Med: Apatinib + Oxaliplatin + Capecitabine Neoadjuvant Therapy for Locally Advanced Gastric Cancer/Gastroesophageal Junction Cancer

BMC Med: Apatinib + Oxaliplatin + Capecitabine Neoadjuvant Therapy for Locally Advanced Gastric Cancer/Gastroesophageal Junction Cancer

 Last Update: 2022-05-25
 Source: Internet
 Author: User

Tags

vanilla gluten free

stadium 25 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Gastric cancer is one of the most common and deadly cancers in China

stomach cancer

Patients with advanced gastric cancer are often treated with drugs

Blood vessel

This study is a single-center, single-arm Phase 2 clinical trial conducted in Shanghai Fudan Zhongshan Hospital, recruiting patients with locally advanced (cT3/4aN+M0) gastric or gastroesophageal junction (GEJ) adenocarcinoma for three courses of treatment of oxaliplatin (135 mg/m2, D1), capecitabine (1000 mg/m2, 2/day, D1-14) and apatinib (250 mg/day, double the dose for the third cycle) Treatment, plus a course of oxaliplatin and capecitabine, followed by gastrectomy + D2 lymphadenectomy

Screening objective response rate was 78.

hypertension

In conclusion, the combination regimen of apatinib, oxaliplatin, and capecitabine as neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma showed reliable efficacy and controllable safety, and it is worth developing 3 Phase clinical trials for further validation

The combination regimen of apatinib, oxaliplatin and capecitabine as neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma showed reliable efficacy and controllable safety .

Tang Zhaoqing,Wang Yan,Yu Yiyi et al.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.